Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
EditorialEditorial

Methotrexate in Our Hearts

LOTTA LJUNG and MARIE HOLMQVIST
The Journal of Rheumatology May 2019, 46 (5) 447-449; DOI: https://doi.org/10.3899/jrheum.181269
LOTTA LJUNG
Umeå University, Department of Public Health and Clinical Medicine/Rheumatology, Umeå; and Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for LOTTA LJUNG
MARIE HOLMQVIST
Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for MARIE HOLMQVIST
  • For correspondence: marie.holmqvist@ki.se
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Undoubtedly, methotrexate (MTX) has a unique place in all rheumatologists’ hearts. It holds the position of first-line treatment choice for rheumatoid arthritis (RA) in the European and North American treatment guidelines for RA1,2,3. The benefit of early start of disease-modifying antirheumatic drugs (DMARD), where MTX is the most preferred, has been increasingly emphasized in the last decade. In 2010 an expert task force published recommendations aiming at maximizing patients’ longterm health-related quality of life, through minimizing disease activity in RA as quickly as possible, with the goals of controlling symptoms, normalizing function, and halting radiographic progression of joint damage4. The treatment strategy is widely known as treat to target, and even though it has been questioned5,6, it is now a cornerstone in the modern approach to RA disease activity and treatment.

In spite of the strong evidence that the drug is a good first choice for our patients, we still might not use it enough, especially when encountering the onset of RA in the elderly. Patients who develop RA at an older age have higher disease activity and disability, but experience a lesser chance of getting intensive treatment with MTX and other DMARD than their younger counterparts7,8.

During the last 20 years we have also become aware that patients with RA have an increased risk of cardiovascular (CV) disease; mainly acute coronary events, but also ischemic stroke. An increased occurrence of traditional risk factors for CV disease does not fully explain the increased risk noted, and it has been suggested that inflammatory activity, and in particular, high disease activity, as seen in active RA, is partly responsible for the risk increase9,10,11.

There are several reports indicating a CV risk reduction associated with MTX treatment in RA12,13. The underlying mechanisms are largely unknown, but in experimental studies MTX has been observed to inhibit key proatherosclerotic cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-614. This could result not only in control of the RA disease activity, but also in beneficial effects on endothelial function and vascular homeostasis. Depending on the background for the observed association between disease activity and CV risk, there are thus several possible explanations for the CV preventive potential of MTX.

No trials have yet been conducted aiming to prove the “inflammatory hypothesis” with MTX treatment in RA. We still await the results from The Cardiovascular Inflammation Reduction Trial, in which patients with a high risk of a second myocardial infarction (but no inflammatory rheumatic disease) were given low-dose MTX or placebo in addition to traditional secondary preventive treatment15. In the CANTOS trial16, however, treatment with the IL-1β inhibitor canakinumab was shown to lower the inflammation and CV events in high-risk patients who were free from inflammatory rheumatic disease. Interestingly, it did so without exerting its effect through reduction of blood lipid levels. In RA, there are observational studies on TNF inhibition and its effect on CV risk, and these studies suggest that it is not the TNF blocking agent per se that reduces the risk of CV disease. It is rather the effect that TNF blockers have on the disease activity that lowers the risks of CV disease in RA. In fact, those who lowered their risk the most were patients who responded to TNF treatment, as opposed to those who did not17,18. The results of these studies might contribute to the understanding of the role of inflammation on CV risk in RA.

With this in mind it is interesting to read the study by Widdifield and colleagues in this edition of The Journal19. The study includes almost 24,000 patients diagnosed with RA after the age of 65, and the authors’ main focus was to assess what effect the actual timing of MTX use has on the risk of CV disease. This is much needed because most studies on MTX and CV risk have focused on MTX as a binary variable (yes/no treatment with MTX), and have not taken into account when the treatment was given in relation to the CV event or RA diagnosis. In this cohort of patients diagnosed with RA somewhat later in life than what we usually see in our practices (mean age 75 yrs at diagnosis), only 35% were treated with MTX within the first year of diagnosis, which is a lot less than what has been reported in other cohorts20, and the incidence of CV disease was higher than what has been reported previously. Both these aspects of course reflect the fact that the patients were older when diagnosed with RA and when followup started. Nonetheless, what the authors beautifully demonstrate is that the timepoint in their disease history when patients were treated with MTX is important; those treated within the last 12 months were at significantly lower risk of a CV event than those who had not been treated with MTX during the last 12 months. Some of this effect could be due to confounding by indication, an issue the authors address in their discussion, and that perhaps is supported by the lower prevalence of comorbidity noted in the MTX-only group. An additional novelty presented related to timeliness, is that there seemed to be a window of opportunity in CV risk prevention, not only in the prevention of joint damage, in RA. The patients who were treated with MTX during the first year of diagnosis were also at decreased risk of CV disease compared to those who were not treated, and even though the effect did not last over time and beyond MTX discontinuation, it is an interesting finding. That these patients were older when they were diagnosed than we usually see is another striking aspect. Maybe we should all ask ourselves whether we are denying our older patients the cardioprotective treatment that MTX provides and that the patients need, probably more often than patients diagnosed in their 40s.

The next step in disentangling through what pathway MTX exerts its cardioprotective effect in RA would of course be to assess the effect of MTX in relation to disease activity, and its relation to response to treatment. A clear association between response (compared with a lack of response) to MTX treatment and the risk of CV disease would support the inflammatory hypothesis, and if no association could be detected it would suggest that MTX indeed acts through other pathways than through lowering inflammation when exerting its protective effect.

Regardless, recent MTX treatment and MTX treatment during the first year of RA diagnosis seems to reduce the risk of CV disease in RA. MTX has a well-deserved place as a first-line DMARD. Maybe now is the time to give MTX its rightful place, along with statins and antihypertensives, in CV prevention in our high-risk patients with RA.

Footnotes

  • See MTX and CVE in elderly RA, page 467

REFERENCES

  1. 1.↵
    1. Smolen JS,
    2. Landewé R,
    3. Bijlsma J,
    4. Burmester G,
    5. Chatzidionysiou K,
    6. Dougados M,
    7. et al.
    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Bykerk VP,
    2. Akhavan P,
    3. Hazlewood GS,
    4. Schieir O,
    5. Dooley A,
    6. Haraoui B,
    7. et al.
    Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39:1559–82.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Singh JA,
    2. Saag KG,
    3. Bridges SL,
    4. Akl EA,
    5. Bannuru RR,
    6. Sullivan MC,
    7. et al.
    2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1–26.
    OpenUrlCrossRef
  4. 4.↵
    1. Solomon DH,
    2. Bitton A,
    3. Katz JN,
    4. Radner H,
    5. Brown E,
    6. Fraenkel L
    . Treat to target in rheumatoid arthritis: fact, fiction or hypothesis? Arthritis Rheumatol 2014;66:775–82.
    OpenUrl
  5. 5.↵
    1. Smolen JS,
    2. Aletaha D,
    3. Bijlsma JW,
    4. Breedveld FC,
    5. Boumpas D,
    6. Burmester G,
    7. et al.
    Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Landewé RBM
    . Overdiagnosis and overtreatment in rheumatology: a little caution is in order. Ann Rheum Dis 2018;77:1394–6.
    OpenUrl
  7. 7.↵
    1. Innala L,
    2. Berglin E,
    3. Moller B,
    4. Ljung L,
    5. Smedby T,
    6. Sodergren A,
    7. et al.
    Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 2014;16:R94.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ruban TN,
    2. Jacob B,
    3. Pope JE,
    4. Keystone EC,
    5. Bombardier C,
    6. Kuriya B
    . The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. Clin Rheumatol 2016;35:759–63.
    OpenUrl
  9. 9.↵
    1. Innala L,
    2. Möller B,
    3. Ljung L,
    4. Magnusson S,
    5. Smedby T,
    6. Södergren A,
    7. et al.
    Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011;13:R131.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Mantel Ä,
    2. Holmqvist M,
    3. Nyberg F,
    4. Tornling G,
    5. Frisell T,
    6. Alfredsson L,
    7. et al.
    Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case–control study. Arthritis Rheumatol 2015;67:2845–54.
    OpenUrl
  11. 11.↵
    1. Sattar N,
    2. McCarey DW,
    3. Capell H,
    4. McInnes IB
    . Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957–63.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Roubille C,
    2. Richer V,
    3. Starnino T,
    4. McCourt C,
    5. McFarlane A,
    6. Fleming P,
    7. et al.
    The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480–9.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Micha R,
    2. Imamura F,
    3. Wyler von Ballmoos M,
    4. Solomon DH,
    5. Hernán MA,
    6. Ridker PM,
    7. et al.
    Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362–70.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Mangoni AA,
    2. Zinellu A,
    3. Sotgia S,
    4. Carru C,
    5. Piga M,
    6. Erre GL
    . Protective effects of methotrexate against proatherosclerotic cytokines: a review of the evidence. Mediators Inflamm 2017;2017:11.
    OpenUrl
  15. 15.↵
    1. Everett BM,
    2. Pradhan AD,
    3. Solomon DH,
    4. Paynter N,
    5. Macfadyen J,
    6. Zaharris E,
    7. et al.
    Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199–207, e15.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Ridker PM,
    2. Everett BM,
    3. Thuren T,
    4. MacFadyen JG,
    5. Chang WH,
    6. Ballantyne C,
    7. et al;
    8. CANTOS Trial Group
    . Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–31.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Dixon WG,
    2. Watson KD,
    3. Lunt M,
    4. Hyrich KL,
    5. Silman AJ,
    6. Symmons DP;
    7. British Society for Rheumatology Biologics Register
    . Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905–12.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Ljung L,
    2. Rantapää-Dahlqvist S,
    3. Jacobsson LT,
    4. Askling J
    . Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis 2016;75:2087–94.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Widdifield J,
    2. Abrahamowicz M,
    3. Paterson JM,
    4. Huang A,
    5. Thorne JC,
    6. Pope JE,
    7. et al.
    Associations between methotrexate use and the risk of cardiovascular events in patients with elderly-onset rheumatoid arthritis. J Rheumatol 2019;46:467–74.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Holmqvist M,
    2. Ljung L,
    3. Askling J
    . Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks. Ann Rheum Dis 2017;76:1642–7.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 5
1 May 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Methotrexate in Our Hearts
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Methotrexate in Our Hearts
LOTTA LJUNG, MARIE HOLMQVIST
The Journal of Rheumatology May 2019, 46 (5) 447-449; DOI: 10.3899/jrheum.181269

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Methotrexate in Our Hearts
LOTTA LJUNG, MARIE HOLMQVIST
The Journal of Rheumatology May 2019, 46 (5) 447-449; DOI: 10.3899/jrheum.181269
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Transfer from Pediatric to Adult Care Is Hardly Child’s Play
  • Real-world Evidence Needs Careful Interpretation
  • Relapsing Polychondritis and Large-vessel Vasculitis
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire